Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Clarke

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|March 14, 2009
Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitorNancy G Wehner, George Shopp, Ingrid Osterburg, et al.
British Dental Journal|August 26, 2022
Career pathways in general dental practice - filling the big voidAbhijit Pal, Janet Clarke, Roshni Karia, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibodyJanet Clarke, Will Leach, Susanne Pippig, et al.
Journal of Immunotoxicology|July 11, 2009
Immunotoxicity profile of natalizumabNancy G Wehner, Carolyn Gasper, George Shopp, et al.
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Regulatory Toxicology and Pharmacology : RTP|November 14, 2007
Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?Janet Clarke, Christopher Hurst, Pauline Martin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 22, 2011
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1aXiao Hu, Kenneth Olivier, Evelyne Polack, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Birth Defects Research. Part B, Developmental and Reproductive Toxicology|March 14, 2009
Postnatal development in cynomolgus monkeys following prenatal exposure to natalizumab, an alpha4 integrin inhibitorNancy G Wehner, George Shopp, Ingrid Osterburg, et al.
British Dental Journal|August 26, 2022
Career pathways in general dental practice - filling the big voidAbhijit Pal, Janet Clarke, Roshni Karia, et al.
Regulatory Toxicology and Pharmacology : RTP|November 18, 2004
Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibodyJanet Clarke, Will Leach, Susanne Pippig, et al.
Journal of Immunotoxicology|July 11, 2009
Immunotoxicity profile of natalizumabNancy G Wehner, Carolyn Gasper, George Shopp, et al.
Cancer Immunology, Immunotherapy : CII|September 10, 2005
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumabCamellia W Adams, David E Allison, Kelly Flagella, et al.
Regulatory Toxicology and Pharmacology : RTP|November 14, 2007
Duration of chronic toxicity studies for biotechnology-derived pharmaceuticals: is 6 months still appropriate?Janet Clarke, Christopher Hurst, Pauline Martin, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 22, 2011
In vivo pharmacology and toxicology evaluation of polyethylene glycol-conjugated interferon beta-1aXiao Hu, Kenneth Olivier, Evelyne Polack, et al.
Regulatory Toxicology and Pharmacology : RTP|August 1, 2014
Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trialsFiona Sewell, Kathryn Chapman, Paul Baldrick, et al.
Pageof 2